tradingkey.logo
tradingkey.logo

Delcath Systems Inc

DCTH
10.140USD
+0.070+0.70%
取引時間 ET15分遅れの株価
358.03M時価総額
227.46直近12ヶ月PER

Delcath Systems Inc

10.140
+0.070+0.70%

詳細情報 Delcath Systems Inc 企業名

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).

Delcath Systems Incの企業情報

企業コードDCTH
会社名Delcath Systems Inc
上場日Oct 19, 2000
最高経営責任者「CEO」Michel (Gerard J)
従業員数96
証券種類Ordinary Share
決算期末Oct 19
本社所在地566 Queensbury Avenue
都市QUEENSBURY
証券取引所NASDAQ OMX - NASDAQ BASIC
United States of America
郵便番号12804
電話番号15187438892
ウェブサイトhttps://delcath.com/
企業コードDCTH
上場日Oct 19, 2000
最高経営責任者「CEO」Michel (Gerard J)

Delcath Systems Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Gerard J. Michel
Mr. Gerard J. Michel
Chief Executive Officer, Director
Chief Executive Officer, Director
330.83K
+3.60%
Ms. Sandra Pennell
Ms. Sandra Pennell
Chief Financial Officer
Chief Financial Officer
70.30K
+15.15%
Mr. Kevin Muir
Mr. Kevin Muir
General Manager - Interventional Oncology
General Manager - Interventional Oncology
21.61K
+16.30%
Mr. John Richard Sylvester
Mr. John Richard Sylvester
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
14.94K
+41.57%
Ms. Martha S. Rook, Ph.D.
Ms. Martha S. Rook, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. David Hoffman
Mr. David Hoffman
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Dr. Bridget A. Martell, M.D.
Dr. Bridget A. Martell, M.D.
Independent Director
Independent Director
--
--
Dr. Vojislav Vukovic, M.D., Ph.D.
Dr. Vojislav Vukovic, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Elizabeth Czerepak
Ms. Elizabeth Czerepak
Independent Director
Independent Director
--
--
Mr. Steven A.J. Salamon
Mr. Steven A.J. Salamon
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Gerard J. Michel
Mr. Gerard J. Michel
Chief Executive Officer, Director
Chief Executive Officer, Director
330.83K
+3.60%
Ms. Sandra Pennell
Ms. Sandra Pennell
Chief Financial Officer
Chief Financial Officer
70.30K
+15.15%
Mr. Kevin Muir
Mr. Kevin Muir
General Manager - Interventional Oncology
General Manager - Interventional Oncology
21.61K
+16.30%
Mr. John Richard Sylvester
Mr. John Richard Sylvester
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
14.94K
+41.57%
Ms. Martha S. Rook, Ph.D.
Ms. Martha S. Rook, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. David Hoffman
Mr. David Hoffman
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
--
--

収益内訳

通貨: USD更新時刻: Mon, Oct 6
通貨: USD更新時刻: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
事業別USD
会社名
収益
比率
HEPZATO KIT
22.50M
93.14%
CHEMOSAT
1.66M
6.86%
会社から関連データがまだ開示されていません。
事業別
地域別
事業別USD
会社名
収益
比率
HEPZATO KIT
22.50M
93.14%
CHEMOSAT
1.66M
6.86%

株主

更新時刻: Thu, Dec 4
更新時刻: Thu, Dec 4
株主統計
種類
株主統計
株主統計
比率
Rosalind Advisors, Inc.
9.35%
The Vanguard Group, Inc.
4.69%
BlackRock Institutional Trust Company, N.A.
4.50%
Simplify Asset Management Inc
1.98%
Geode Capital Management, L.L.C.
1.95%
他の
77.53%
株主統計
株主統計
比率
Rosalind Advisors, Inc.
9.35%
The Vanguard Group, Inc.
4.69%
BlackRock Institutional Trust Company, N.A.
4.50%
Simplify Asset Management Inc
1.98%
Geode Capital Management, L.L.C.
1.95%
他の
77.53%
種類
株主統計
比率
Hedge Fund
20.47%
Investment Advisor
17.51%
Investment Advisor/Hedge Fund
8.95%
Venture Capital
2.90%
Individual Investor
2.74%
Research Firm
2.40%
Pension Fund
0.35%
Bank and Trust
0.09%
Insurance Company
0.03%
他の
44.55%

機関投資家保有株

更新時刻: Mon, Dec 8
更新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
238
18.04M
62.08%
+1.07K
2025Q3
242
18.04M
64.94%
-422.09K
2025Q2
221
18.52M
54.81%
+2.84M
2025Q1
160
15.18M
51.87%
-2.16M
2024Q4
134
13.70M
43.13%
+3.02M
2024Q3
103
10.42M
51.90%
-86.02K
2024Q2
84
10.50M
46.11%
+479.32K
2024Q1
71
8.41M
37.64%
-1.16M
2023Q4
72
6.53M
41.36%
-1.60M
2023Q3
66
8.03M
51.77%
+1.12M
詳細を見る

株主動向

会社名
保有株式数
比率
変動額
変動率
日付
Rosalind Advisors, Inc.
3.30M
9.43%
-113.08K
-3.31%
Jun 30, 2025
The Vanguard Group, Inc.
1.61M
4.6%
+216.71K
+15.55%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.56M
4.45%
+1.39M
+821.60%
Jun 30, 2025
Geode Capital Management, L.L.C.
703.17K
2.01%
+394.90K
+128.10%
Jun 30, 2025
State Street Investment Management (US)
473.89K
1.35%
+360.15K
+316.63%
Jun 30, 2025
Vivo Capital, LLC
569.53K
1.63%
-180.67K
-24.08%
Jun 30, 2025
Citadel Advisors LLC
803.21K
2.3%
+677.66K
+539.74%
Jun 30, 2025
詳細を見る

関連ETF

更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
Simplify Propel Opportunities ETF
3.79%
ALPS Medical Breakthroughs ETF
0.14%
iShares Micro-Cap ETF
0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.05%
iShares Russell 2000 Growth ETF
0.02%
Global X Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0.01%
詳細を見る
Simplify Propel Opportunities ETF
比率3.79%
ALPS Medical Breakthroughs ETF
比率0.14%
iShares Micro-Cap ETF
比率0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
比率0.05%
iShares Russell 2000 Growth ETF
比率0.02%
Global X Russell 2000 ETF
比率0.01%
ProShares UltraPro Russell2000
比率0.01%
Proshares Ultra Russell 2000
比率0.01%
iShares Russell 2000 ETF
比率0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
比率0.01%

配当金

過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし

株式分割

日付
種類
比率
データなし
日付
種類
比率
データなし

よくある質問

Delcath Systems Incの上位5名の株主は誰ですか?

Delcath Systems Incの上位5名の株主は以下のとおりです。
Rosalind Advisors, Inc.は3.30M株を保有しており、これは全体の9.43%に相当します。
The Vanguard Group, Inc.は1.61M株を保有しており、これは全体の4.60%に相当します。
BlackRock Institutional Trust Company, N.A.は1.56M株を保有しており、これは全体の4.45%に相当します。
Geode Capital Management, L.L.C.は703.17K株を保有しており、これは全体の2.01%に相当します。
State Street Investment Management (US)は473.89K株を保有しており、これは全体の1.35%に相当します。

Delcath Systems Incの株主タイプ上位3種は何ですか?

Delcath Systems Incの株主タイプ上位3種は、
Rosalind Advisors, Inc.
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.

Delcath Systems Inc(DCTH)の株式を保有している機関の数はいくつですか?

2025Q4時点で、Delcath Systems Incの株式を保有している機関は238社あり、保有株式の総市場価値は約18.04Mで、全体の62.08%を占めています。2025Q3と比較して、機関の持ち株は-2.85%増加しています。

Delcath Systems Incの最大の収益源は何ですか?

FY2025Q2において、HEPZATO KIT部門がDelcath Systems Incにとって最大の収益を生み出しており、その金額は22.50Mで、全収益の93.14%を占めています。
KeyAI